Navigation Links
Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement
Date:7/21/2009

DOYLESTOWN, Pa., July 21 /PRNewswire/ -- Avidas Pharmaceuticals and LaRon Pharma Inc. today announced that they have entered into an agreement for LaRon to co-promote Avidas' key prescription-only convenience kits, Avidoxy(TM) DK defence kit and Scalacort(TM) DK defence kit. Under the terms of the agreement, LaRon will provide sales support focused on primary care and internal medicine physicians in the United States, while Avidas will continue its sales force specialty focus in dermatology. Avidas will also maintain full marketing rights for each of the products. Specific financial terms of the deal were not disclosed.

"We are very excited to strengthen our position in the severe acne and scalp dermatitis markets with this LaRon collaboration," said Margie Gardner, CEO of Avidas. "The addition of LaRon's sales force efforts, together with the efforts of our own sales team, will significantly expand our footprint into primary care while allowing us to maintain our focus on the specialty market of dermatology."

The Avidoxy DK defence kit includes Avidoxy (Doxycycline Tablets), a broad spectrum oral antibiotic, in an easy-to-swallow film-coated caplet indicated as adjunctive therapy for severe acne, along with complimentary defence(TM) acne wash, a specially formulated oil- and alcohol-free acne wash with 2% salicylic acid that provides gentle, yet effective, cleansing and exfoliation of skin. Avidoxy DK defence kit also includes complimentary defence(TM) solare SPF 30+, a lightweight, oil-free, non-comedogenic sunscreen rich in anti-oxidants and moisturizers offering the broad spectrum sun protection that is so important for patients with acne.

Scalacort DK defence kit includes Scalacort (hydrocortisone lotion USP) 2%, a fast-drying, non-greasy corticosteroid in a clear, fragrance-free base. Scalacort relieves itching and inflammation of the scalp in areas where greasy ointm
'/>"/>

SOURCE Avidas Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Texas Senator Kirk Watson Honored as 'Champion for Children' by the AMERIGROUP Foundation 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:FEW Announces Legislative Goals for Remainder of 110th Congress; Delivers Fact Sheets to Legislators 2Health News:The Rocky Mountain Hospital for Children at Presbyterian/St. Luke's is now Member of the Children's Oncology Group 2Health News:Bionovo to Present at the Cambria Capital Investor Meeting 2Health News:Bionovo to Present at the Cambria Capital Investor Meeting 3Health News:Scientists Isolate Organism That Causes Disfiguring Tropical Disease 2
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Ascension Orthopedics Hires Key Senior Executives 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 1Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 3Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 4Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 5How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 1How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 2How Well Do You Sleep At Night 3F Visit The New Online Aviisha Medical Wellness Institute To Find Out 54874 3Misuse of Pain Medication Draws Heightened Concerns 54870 1Misuse of Pain Medication Draws Heightened Concerns 54870 2Misuse of Pain Medication Draws Heightened Concerns 54870 3Misuse of Pain Medication Draws Heightened Concerns 54870 4